Gregg Feinerman, MD, FACS, Feinerman Vision, Newport Beach
For most of my career, “getting your eyes fixed” meant LASIK. That is changing, and the data now confirm what I have watched happen in my own exam rooms.
On September 10, 2026, STAAR Surgical, the maker of the EVO ICL™, released a seven-market report called The Future of Refractive Surgery. Its headline United States finding: laser vision correction procedures have fallen 52 percent since 2022, four consecutive years of double-digit decline, while EVO ICL adoption rose 76 percent over the same period and more than tripled its share of the market.
United States, 2022 to 2026
Laser vision correction procedures: down 52 percent. EVO ICL adoption: up 76 percent, with market share more than tripled. Source: STAAR Surgical, The Future of Refractive Surgery, September 2026, company analysis of US procedure volume and EVO ICL unit sales, FY2022 to FY2026.
My practice is a window on the same trend. In the second quarter of 2025, EVO ICL accounted for 18 percent of our refractive surgery patients. In the second quarter of 2026, it was 36 percent. Our numbers doubled in one year, and I did not change how I evaluate anyone. Patients are arriving with different questions and different priorities.
This post explains what is driving the shift, where LASIK still belongs, and how to think about your own decision if you are in your 20s or 30s and researching vision correction right now.
What the numbers actually show
A word on sourcing before the figures. STAAR manufactures the EVO ICL, so this is industry research, not an independent academic study. I am citing it because the volume data align with what surgeons across the country have been reporting for several years and with what I see in my own practice, and because it is the first report to put the pieces together across markets. Read it with that context.
United States procedure volumes (2022 to 2026). Laser procedures indexed to 2022 fell to roughly 48 percent of their 2022 level. EVO ICL units rose to roughly 176 percent of their 2022 level. (STAAR, The Future of Refractive Surgery, 2026, page 4.)
What high-prescription patients are choosing. In a 2024 study by the American-European Congress of Ophthalmic Surgery covering 1,882 procedures across 19 US practices, the implantable collamer lens was the most common choice, at 72 percent, for patients at -8.00 diopters and above. For prescriptions beyond -10.00, the lens was chosen 81 percent of the time in 2025, up from 67 percent in 2022. (AECOS practice-pattern data as reported by STAAR, 2026, pages 5 and 6.)
What patients say they want. In STAAR’s US consumer survey of 1,800 adults (fielded August 2025), 86 percent want to be free of glasses and contacts, 61 percent are attracted to a procedure that is reversible, and 54 percent say they are not open to laser correction. The top barriers to laser were safety concerns (27 percent) and fear of the procedure (21 percent). Cost was named by 4 percent. Only 19 percent had heard of the implantable collamer lens unprompted, compared with 79 percent for LASIK. (Pages 3 and 19.)
That last pair of numbers is the story in miniature. Most Americans who want vision correction have never heard of the option that is growing fastest.
Independent corroboration. Market Scope, the ophthalmic industry’s independent market research firm, is not affiliated with any lens or laser manufacturer. In January 2026 it reported that US refractive surgery volumes hit a record low in 2025, noting that the US market “has experienced a sharper drop since 2021” than the global market. Its quarterly surgeon surveys put US refractive procedure volume down 17.3 percent in the fourth quarter of 2025 and down 9.5 percent in the first quarter of 2026, each compared with the same quarter a year earlier, while cataract and lens procedures grew. For scale, Market Scope has placed the US LASIK peak at roughly 1.4 million procedures a year around 2000 to 2001; the market today is a fraction of that.
The trend did not begin with this report. In 2024, refractive surgeons interviewed by EyeWorld described “a pretty substantial shift from LASIK to IOL-based procedures, such as ICLs, and refractive lens exchange,” with patients who would have had LASIK a few years earlier now being recommended a lens. Japan, the most mature lens market, already performs more than half of its refractive procedures with an implantable lens.
In our practice, one year apart
EVO ICL as a share of Feinerman Vision refractive surgery patients: 18 percent in the second quarter of 2025, 36 percent in the second quarter of 2026. Same surgeon, same evaluation, different patient priorities.
Four reasons the shift is happening
1. Candidacy widened. LASIK and PRK correct vision by removing corneal tissue. The higher your prescription and the thinner your cornea, the less margin there is, which is why so many people were told “you are not a candidate” and stopped looking. EVO ICL is a Collamer® lens placed inside the eye, behind the iris and in front of your natural lens. It removes no corneal tissue, so thin corneas are not a barrier, and it is FDA approved for nearsightedness from -3.00 to -20.00 diopters, with or without astigmatism, in adults 21 to 60. People who were turned away from LASIK are now candidates for something. EVO ICL for thin corneas and EVO ICL for high prescriptions cover each case in detail.
2. Reversibility became a priority. Six in ten US survey respondents said a reversible option appeals to them. LASIK permanently reshapes the cornea. EVO ICL is reversible: the lens can be removed or exchanged by a surgeon if your needs change. That matters most decades later, when the natural lens ages and lens replacement surgery becomes the conversation. A prior EVO ICL preserves the full menu of replacement lenses, including trifocals. Prior LASIK usually narrows that menu to a monofocal or the Light Adjustable Lens™, both because LASIK, particularly for higher prescriptions, degrades optical quality, and because lens power calculations are less predictable after any corneal laser procedure. I wrote about a patient who lived this out in the 20-year reversibility case study, and the long-term logic is laid out in EVO ICL and your future choices.
3. Dry eye moved to the front of the conversation. Patients now arrive having read first-person accounts of post-LASIK dry eye. LASIK creates a corneal flap and cuts corneal nerves, and for most people the effect is temporary, but not for everyone. EVO ICL involves no flap and leaves the corneal nerves largely undisturbed, so its dry eye impact is lower. In a published study of patients 5 to 15 years after surgery, laser vision correction patients showed significantly higher rates of tear hyperosmolarity, a marker of tear film instability, than non-surgical controls, while implantable collamer lens patients showed no difference from controls (Gjerdrum B, et al. Clin Ophthalmol. 2020;14:269-279).
4. The research happens before the consultation. More than half of US respondents said they would use a search engine to research vision correction, and a quarter would ask an AI tool. Patients are walking in already knowing that SMILE, PRK, and LASIK all remove corneal tissue, already aware that a lens-based option exists, and already asking about the trade-offs. That is a healthy starting point for a medical decision, and I welcome it.
Where LASIK still belongs
None of this means LASIK is obsolete, and I would be misleading you if I said so. I perform LASIK with WaveLight® Plus, and for the right eye it produces exceptional results: in the published outcomes study, 100 percent of treated eyes saw 20/20 or better and half saw 20/12.5 (He C, Bala C. J Cataract Refract Surg. 2023;49(11):1140-1146). The WaveLight Plus page explains the ray-tracing technology behind those numbers.
LASIK remains a strong choice when a patient has a stable, moderate prescription, a healthy cornea with adequate thickness, no meaningful dry eye history, and is under age 45. It is fast (about 15 minutes for both eyes), recovery is quick, and at Feinerman Vision it carries a lifetime enhancement guarantee. If that describes your eyes, LASIK may well be the better answer, and I will tell you so.
The change in the market is not that LASIK stopped working. It is that the population LASIK serves best turned out to be narrower than the marketing of the 2000s suggested, and the alternative for everyone else finally matured.
If you are over 40, the shift is about a different lens
The report focuses on laser versus phakic lens, but there is a parallel movement among older patients toward refractive lens exchange (RLE). Beginning in the 40s, the natural lens stiffens and clouds, a process I describe to patients as dysfunctional lens syndrome. Reading vision fades, night vision degrades, and no corneal procedure fixes the underlying cause. That is why I generally do not recommend LASIK over 45; the aging lens, not the cornea, is usually the real problem.
RLE replaces the aging lens with an implant chosen for your anatomy and goals, using the same platform as cataract surgery but performed earlier and electively. Between roughly 45 and 50, when the natural lens is still clear, EVO ICL is often the better fit; past 50, RLE usually is. If this describes you, the refractive lens exchange page is the right starting point, and the EVO ICL versus RLE comparison explains how age determines which lens approach fits.
What the shift costs, and what it does not
A lens procedure costs more than a laser procedure up front, and you deserve the figures rather than a “call for pricing” page.
Feinerman Vision pricing, September 2026
EVO ICL: $9,450 for both eyes, all-inclusive (consultation and imaging, the lenses, the procedure, and every post-operative visit). LASIK: from $4,100 for both eyes. WaveLight Plus LASIK: $5,100. Refractive lens exchange: priced per eye by lens choice. All pricing is subject to change.
Refractive lens exchange is priced per eye and depends on the lens selected; the RLE cost page shows ranges by lens type. Advertised laser prices elsewhere often exclude pre-operative testing, enhancements, and follow-up care, so ask what is included before comparing any two numbers. The full breakdowns are on the EVO ICL cost page and the LASIK cost page.
How I evaluate this in the exam room
The trend tells you what the population is doing. It does not tell you what your eyes need. In a consultation I evaluate candidacy across every modern option, LASIK, PRK, SMILE, EVO ICL and Refractive Lens Exchange.
For EVO ICL specifically, the step that separates a good result from a great one is lens sizing, which we do with UBM AI™ ultrasound biomicroscopy and ICLguru® rather than estimating from surface measurements. I have worked with the implantable collamer lens for more than 20 years: I was the first surgeon in California to implant the Visian ICL after its 2005 FDA approval and among the first in California with EVO ICL after its 2022 approval. More than 4 million implantable collamer lenses have been sold worldwide, and among patients studied, the implantable collamer lens carries a 99.4% satisfaction rate.
Whatever we choose, you get one surgeon from consultation through every follow-up. I call you the evening of surgery, see you myself the next morning, and ask you to save my cell phone number so you can reach me directly with any question.
Frequently asked questions
Is LASIK really declining in the United States?
Yes. STAAR Surgical’s 2026 report documents a 52 percent decline in US laser vision correction procedures from 2022 to 2026, with double-digit losses each year. Surgeons have described the same shift toward implantable lenses and refractive lens exchange since at least 2024. LASIK remains an excellent procedure for the right candidate; the decline reflects patients and surgeons choosing lens-based options for eyes that laser serves less well.
Why are more people choosing EVO ICL over LASIK?
The most common reasons are wider candidacy (thin corneas and prescriptions up to -20.00 diopters are not barriers), reversibility, lower dry eye impact because no corneal flap is created, and the fact that a prior EVO ICL preserves every lens option for later in life. See EVO ICL vs. LASIK for the full comparison.
Is EVO ICL reversible?
EVO ICL is reversible. The lens can be removed or exchanged by a surgeon if your needs change. That preserves your future options, including trifocal lenses at the time of lens replacement surgery.
Does the shift toward lenses mean I should not get LASIK?
Not necessarily. If you have a stable, moderate prescription, a healthy cornea of adequate thickness, no significant dry eye, and are under about 45, LASIK with WaveLight Plus may be the better option for you. Candidacy is determined at an in-person evaluation, not by a trend.
What about SMILE or PRK instead of LASIK?
SMILE and PRK are also corneal laser procedures that remove tissue, so they are usually ruled out for the same reasons LASIK is: corneas that are too thin or prescriptions that are too high. PRK can be an option for mildly thin corneas. Dr. Feinerman evaluates every patient across LASIK, PRK, SMILE, EVO ICL and Refractive Lens Exchange.
I am over 45. Does any of this apply to me?
Yes. The shift from laser to lens applies to you too; what changes with age is which lens. Between roughly 45 and 50, EVO ICL is often still the better fit: it is FDA approved through age 60 and corrects distance vision without touching the cornea or the natural lens. Past 50, the natural lens itself has usually begun to stiffen and cloud, and refractive lens exchange (RLE) addresses that directly by replacing it with a lens chosen for your eyes. Dr. Feinerman generally does not recommend LASIK over 45; the aging lens, not the cornea, is usually the real problem. The right approach depends on your prescription and the condition of your natural lens, which is determined at the evaluation.
Related reading
- EVO ICL in Newport Beach (Pillar)
- EVO ICL vs. LASIK
- EVO ICL for Thin Corneas
- EVO ICL for High Prescriptions
- EVO ICL and Your Future Choices
- Which Procedure Is Right for Me?
Find out which side of the shift your eyes are on
The market is moving toward lens-based vision correction because, for a large share of eyes, it is the better fit. Whether yours is one of them is a question for an examination, not a trend line. The candidacy quiz covers every procedure I evaluate. Book your evaluation with Dr. Feinerman in Newport Beach: (949) 631-4780 or FeinermanVision.com.